Abstract 919P
Background
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET-CT) is a non-invasive imaging modality. This study aimed to investigate the effects of radiometric parameters and clinical characteristics of 18F-FDG PET-CT on the prognosis of patients with nasopharyngeal carcinoma (NPC).
Methods
A total of 801 patients with metastatic NPC were enrolled between 2016 and 2020, and all participants underwent 18F-FDG PET/CT before treatment. We assessed the following 18F-FDG PET parameters: standardized uptake value (SUV), SUV-avg (average), SUV-peak (maximum), and total lesion glycolysis (TLG) of the primary tumor and regional lymph nodes. We used multivariate Cox proportional hazards models and multiple machine learning techniques to identify independent predictors of survival based on radiomic parameters and patient clinical characteristics. After selecting the features, we established prognosis models using a COX stepwise regression model. Finally, we performed internal validation, and a nomogram was created for NPC comprehensive diagnosis.
Results
In this study, we developed a stable and robust model incorporating five independent prognostic features based on COX regression. The area under the curve (AUC) of the model was 0.75 (95% CI = 0.52–0.97) at 1 year, 0.80 (95% CI = 0.71–0.89) at 3 years, and 0.86 (95% CI = 0.78–0.94) at 5 years. The AUC at 3 years and 5 years were calculated as 0.7276 and 0.7242, respectively. The model was validated using receiver operating characteristic (ROC), consistency index, and multivariate analysis, which showed high accuracy and consistent performance. Moreover, patients in the low-risk score group exhibited significantly better outcomes than those in the high-risk score group (P < 0.001).
Conclusions
Our findings suggest that age, SUV-Tmax, SUV-Tavg, SUV-Tpeak, and TLG-T are valuable parameters for predicting long-term survival in patients with NPC. The nomogram based on metabolic parameters combined with other variables showed good prognostic accuracy in predicting NPC prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12